Orexo

Orexo is a publicly traded Swedish pharmaceutical company that has evolved from an R&D-focused entity into a commercial organization with a hybrid business model. Its strategic foundation is the proprietary AmorphOX® powder-based drug delivery technology, designed to improve bioavailability and stability for critical medicines. Following the transformative 2025 divestment of its flagship product Zubsolv® in the US, the company is executing a three-pillar growth strategy focused on becoming a global leader in nasal powder delivery, advancing a diversified pipeline to key value inflection points, and establishing technology partnerships.

AmorphOX® is a proprietary, powder-based drug delivery technology that enhances bioavailability and stability for both small and large molecules, enabling novel administration routes like intranasal delivery and potentially eliminating cold-chain requirements.

Orexo competes with auto-injector and nasal spray makers in rescue medicine, differentiated by AmorphOX's stability profile. As a platform, it competes with other drug delivery firms, but its proven success with both small and large molecules in a stable powder format creates a unique niche for nasal and thermostable delivery.